Back to results
US 2026/0108554 A1Published application
Methods for reprogramming and gene editing cells
AssigneeFactor Bioscience Inc.
InventorsMatthew ANGEL, Christopher ROHDE, Ian HAY, Ismet Caglar TANRIKULU, Tae Yun KIM, Abigail BLATCHFORD, Mackenzie PARMENTER
Life of this patent
Estimating the term…
Abstract
The present disclosure provides improved methods for reprogramming and gene editing cells, including manufacturing a population of cells comprising cells of the lymphoid lineage and/or cells of the myeloid lineage.
Claims21
-59. (canceled)
A method of engineering a cell, the method comprising
- (a) contacting a cell with a synthetic RNA encoding a gene-editing protein, wherein the gene-editing protein generates a break in a target site of a beta-2-microglobulin (B2M) gene, and
- (b) delivering to the cell a repair template comprising a nucleic acid sequence, wherein the nucleic acid sequence encodes an HLA-E polypeptide, wherein the nucleic acid sequence is inserted at the break in the target site of the B2M gene,
- thereby generating an engineered cell.
An engineered cell comprising a disruption in a B2M gene, wherein the engineered cell expresses a fusion protein comprising a fragment of a B2M polypeptide and a HLA-E polypeptide.
Dependencies are inferred from the claim text.